Scientist behind Russia coronavirus vaccine defends ‘wartime’ rollout during trial.

Global News

Breaking news & current latest Canadian news headlines; national weather forecasts & predictions, local news videos, money and financial news; sports stats and scores.

Click to play video 'UNGA 2020: Russia’s Putin proposes COVID-19 vaccine cooperation conference'

UNGA 2020: Russia's Putin proposes COVID-19 vaccine cooperation conference

Russia plans to share preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants, raising the tempo in an already frenzied global race to end the pandemic.

Alexander Gintsburg, head of the Gamaleya Institute that produced the Sputnik V vaccine, told Reuters that the pace of its development was necessary under the “wartime” conditions of a pandemic but no corners were being cut.

Russia has pushed ahead with its potential COVID-19 vaccine at top speed with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was prioritizing national prestige over solid science and safety.

“People are dying just like during a war,” said Gintsburg, holding a crystal model of a coronavirus in his hand. “But this fast-tracked pace is not synonymous, as some media have suggested, with corners being cut. No way.”

Sitting in his wood-paneled office at the institute in Moscow, Gintsburg said his team had been set a tight deadline to produce a vaccine but all the guidelines for testing Sputnik V’s safety and efficacy had been followed.

The plan to publish interim results based on the first 42 days of monitoring volunteers means Russia has a high chance of becoming the first worldwide to announce any data from a final-stage trial, which is known as Phase III.

The first of 5,000 volunteers was vaccinated on Sept. 9, which means interim results could be issued some time after Oct. 21. Russia’s sovereign wealth fund, which has invested in the vaccine’s roll-out, has said it expects interim results to be published in October or November.

Public interest in sharing info

Several Western developers are conducting final-stage trials that have already been going on for more than 42 days but have not published any interim results.

Drugmakers have said they would wait until they have enough infections to get a reliable read-out from the data before publication, rather than assigning a specific date.

Gintsburg said there was a public interest argument for sharing interim results after 42 days as they would show the general trend in the data.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

“For me, for example, it is too short. But for people who are interested in how things are going, it is already too long.”

Gintsburg said volunteers would be monitored for 180 days after the last of 40,000 participants was vaccinated. Six months on, his team planned to tally up final results and then publish them in an international journal.

Their early-stage trial results were peer-reviewed and published in The Lancet.

In parallel with the trial, Russia began inoculating members of the general public considered at high risk on Sept. 8, another unconventional move by Moscow in the race for a vaccine.

Trending Stories

About 400 people have been inoculated so far, according to the health ministry. They undergo a less rigorous medical exam than trial volunteers, though they can submit data about their health following inoculation via an online platform.

A government source told Reuters the interim Phase III trial results would likely inform a decision on whether to expand this mass inoculation drive, starting with people over 60.

Big plans for further testing

Gintsburg said no serious side-effects had been reported during the Phase III trial so far, while minor, anticipated side-effects had occurred among just 14% to 15% of the volunteers. A quarter of the participants receive a placebo.

He also defended the vaccine’s early registration for public use, saying it was the most ethical approach.

“The choice was between giving people the opportunity to protect themselves, or letting them play roulette with this deadly infection.”

He also said Russia was aiming for the vaccine to be about 75% more effective than a placebo, which is above the 50% threshold for COVID-19 vaccines set by the U.S. Food and Drug Administration.

Gintsburg said having 40,000 trial participants meant the trial would be effective even with low levels of COVID-19 transmission in the Russian capital.

“It guarantees that even with a low infection rate, we would still have statistically significant data.”

Moscow registered 642 new cases of COVID-19 the day the trial began. The infection rate has risen since, with 2,217 new cases on Monday, though that’s still well below a peak of around 6,000 daily infections in the capital in early May.

Other vaccine-makers have launched mass trials in countries such as Brazil, South Africa and the United States, searching for places where the disease is still rife after the epidemic came down from its peak in Europe.

Russia also plans to test in several countries, including Belarus, Brazil and India.

Race against other countries

Drugmakers have also pledged to ensure their larger clinical trials include diverse sets of volunteers in terms of race, ethnicity, gender, age and other factors.

Russia is setting Phase III quotas by age to ensure a sufficient number of elderly participants, Gintsburg said, but no other special groups were being formed. Over a fifth of those vaccinated in the trial so far have been over 50, he said.

The rate of transmission among trial participants affects the timing of when many vaccine-makers plan to publish interim results as they need to record a certain number of COVID-19 infections before early data can be shared.

British drugmaker AstraZeneca launched a Phase III trial for its vaccine in May and has not yet disclosed any trends.

U.S. pharmaceutical giant Pfizer, which is developing a vaccine with German partner BioNTech, and U.S. vaccine maker Moderna both began their trials in late July. Neither has made any preliminary disclosures yet.

BioNTech has said it may have data for a regulatory filing by the end of October or early November.

In a bid to speed up the process of finding a vaccine, Britain is planning to host trials where volunteers are deliberately infected with COVID-19.

Gintsburg said this kind of trial was impossible in Russia and considered unethical: “We were surprised by the news.”

(Reporting by Polina Ivanova and Polina Nikolskaya; Additional reporting by Ludwig Burger; Writing by Polina Ivanova; Editing by Josephine Mason and David Clarke)

View link »

© 2020 Reuters

Related news

How the presidential election could affect the Canada-U.

The United States is the epicentre of the virus, with more than 8.5 million infections and a death toll greater than 225,000.

Workhorse Russian Tu-154 Passenger Jet Flies Into Retirement.

The last Tu-154 passenger jet still in service in Russia has completed its final scheduled commercial flight.

COVID-19: Iran's Parliament Speaker Tests Positive; Russia Tightens Restrictions.

Here's a roundup of COVID-19 developments in RFE/RL's broadcast regions.


Ukraine reports 7,474 new coronavirus cases

Ukraine has recorded 7,474 new coronavirus cases in the past 24 hours, bringing the total number of confirmed COVID-19 cases to 363,075, according to the interactive map of the National Security and Defense Council of Ukraine.

Amid China Concern In IndoPacific, Mike Pompeo Meets Sri Lankan President.

US Secretary of State Mike Pompeo today called on Sri Lankan President Gotabaya Rajapaksa and discussed a range of bilateral issues, including economic partnership based on transparent trade and...

Biden Insists He'll Tackle Coronavirus As Trump Pushes «Super-Recovery» .

Joe Biden flayed Donald Trump on Tuesday with accusations the US President has surrendered to a surging pandemic, as the Democrat took his campaign to the Republican stronghold of Georgia one week...

Lukashenko accuses Poland, Lithuania of funding Belarus workers' strike.

The most -proactive strikers allegedly receive funding from abroad, he claims.

U.S. Congressional Ukraine Caucus Worried Nord Stream 2 Sanctions Bill Could Be Dropped

Members of the Congressional Ukraine Caucus are concerned a U.S. bill to expand sanctions on a Russian natural-gas pipeline to Europe could be dropped from the 2021 National Defense Authorization Act (NDAA). 


Qatar Expresses Regret Amid Row Over Strip-Search Of Women On Flight.

Qatar said Wednesday it "regrets" infringing personal freedoms, as it explained invasive examinations of female passengers during a search for an abandoned baby's mother at Doha airport.

Trump Wants Putin To ‘Join Forces’ On China, Former Adviser Says.

WASHINGTON -- President Donald Trump would focus in a second term on getting Russian President Vladimir Putin to side with him in his confrontation with China, a former adviser said.

By continuing to browse World News (UAZMI), you acknowledge that you have read the Terms of Use and agree to the use of cookies